GSK is on the hunt for deals in China after the UK drugmaker rebuilt a “very strong” relationship with the government and local companies since a corruption scandal a decade ago.Chief commercial officer Luke Miels told the Financial Times that the company was working on further deals with Chinese companies after it signed a licensing agreement in October worth up to $1.5bn for a cancer drug developed by Hansoh Pharma.
葛蘭素史克(GSK)正在中國尋覓交易。自10年前爆出腐敗丑聞以來，這家英國制藥商與政府和當地企業重建了“非常牢固”的關系。
您已閱讀11%（482字），剩余89%（3770字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。